Escalon(R) (ESMC) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
More News related to ESMC
- Escalon Medical (ESMC) Sells 1.15M Shares in Private Placement
- Escalon(R) (ESMC) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
- Escalon Medical (ESMC) Receives FDA 510(K) Clearance For VascuView(TM)
- Escalon Medical (ESMC) Subsidiary Receives FDA 510(k) Clearance
- Escalon Medical (ESMC) Receives FDA 510(K) Clearance for D3 Hematology System
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Escalon Medical Corp. (Nasdaq: ESMC) announced that the United States Food and Drug Administration has cleared the 510(k) submission for the LIASYS(TM) bench top clinical chemistry and immunoturbidimetric analyzer. The Company's recently acquired JAS Diagnostic ("JAS") unit is the distributor for the LIASYS analyzer in the United States and supplier of the associated chemistry reagents. JAS prepared and submitted the 501(k) application on behalf of the manufacturer, Analyzer Medical System, headquartered in Rome, Italy. The analyzer is being introduced at the 2008 Annual Meeting for the American Association for Clinical Chemistry ("AACC") currently being held in Washington D.C.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
